Physician profile
Michelle Purtle
NPI 1659364222
$6,864.11
in general payments reported to CMS, 2019-2025
23 companies · $3,256 in 2025
The $3,256 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $748 · 2023: $1,115 · 2024: $1,191 · 2025: $3,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,888 · Consulting Fee: $1,320 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,888.14 |
| Consulting Fee | $1,320.00 |
| Education | $353.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,449.36 | 2025 | Dupixent |
| Janssen Biotech, INC. | $1,036.06 | 2023-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $825.49 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $482.71 | 2021-2025 | |
| Abbvie INC. | $473.79 | 2022-2025 | |
| Incyte Corporation | $402.13 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $397.87 | 2021-2025 | |
| Amgen INC. | $314.98 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $307.26 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Pfizer INC. | $277.41 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $173.69 | 2021-2023 | Dupixent |
| Arcutis Biotherapeutics, INC. | $146.67 | 2024-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.77 | 2022-2023 | Jublia, Duobrii, Arazlo |
| Organon LLC | $75.34 | 2025 | Vtama |
| Medline Industries Lp | $70.49 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $69.42 | 2024-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $58.75 | 2023-2025 | |
| Almirall LLC | $47.84 | 2021-2022 | |
| Epi Health, LLC | $47.56 | 2022 | |
| Ucb, INC. | $46.86 | 2022-2024 | Cimzia, Bimzelx |
| Leo Pharma INC. | $33.33 | 2021 | |
| Lilly USA, LLC | $20.37 | 2023 | Olumiant, Taltz |
| Dermavant Sciences, INC. | $17.96 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Purtle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.